CareDx Inc (CDNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CareDx Inc (CDNA) has a cash flow conversion efficiency ratio of 0.120x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($37.36 Million) by net assets ($311.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CareDx Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how CareDx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CDNA total debt and obligations for a breakdown of total debt and financial obligations.
CareDx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CareDx Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Appotronics Corp Ltd
SHG:688007
|
0.029x |
|
Shanghai Pudong Road & Bridge Construction Co Ltd
SHG:600284
|
0.035x |
|
Nanxing Furniture Machinery & Equipment Co Ltd
SHE:002757
|
0.075x |
|
PLAYTIKA HOLDING DL-01
F:8II
|
-0.695x |
|
Fujian Tianma Science and Technology Group Co Ltd
SHG:603668
|
-0.005x |
|
Tortoise Energy Infrastructure Closed Fund
NYSE:TYG
|
0.017x |
|
Jiangsu Tongli Risheng Machinery Co. Ltd.
SHG:605286
|
-0.069x |
|
Cronos Group Inc
TO:CRON
|
0.012x |
Annual Cash Flow Conversion Efficiency for CareDx Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of CareDx Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see CareDx Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $378.43 Million | $38.05 Million | 0.101x | +242.89% |
| 2023-12-31 | $261.33 Million | $-18.39 Million | -0.070x | -20.13% |
| 2022-12-31 | $430.91 Million | $-25.24 Million | -0.059x | -41.43% |
| 2021-12-31 | $465.88 Million | $-19.29 Million | -0.041x | -134.40% |
| 2020-12-31 | $277.68 Million | $33.43 Million | 0.120x | +530.45% |
| 2019-12-31 | $99.00 Million | $-2.77 Million | -0.028x | +33.04% |
| 2018-12-31 | $95.93 Million | $-4.01 Million | -0.042x | -101.74% |
| 2017-12-31 | $-5.95 Million | $-14.31 Million | 2.403x | +387.38% |
| 2016-12-31 | $19.76 Million | $-16.52 Million | -0.836x | -152.88% |
| 2015-12-31 | $29.49 Million | $-9.75 Million | -0.331x | -307.61% |
| 2014-12-31 | $41.30 Million | $-3.35 Million | -0.081x | -2338.51% |
| 2013-12-31 | $-150.67 Million | $-546.00K | 0.004x | -69.96% |
| 2012-12-31 | $-147.20 Million | $-1.78 Million | 0.012x | -- |
About CareDx Inc
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution … Read more